Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-64041757 |
Synonyms | |
Therapy Description |
JNJ-64041757 (pemlimogene merolisbac) is a immunotherapy based on live attenuated Listeria monocytogenes, which may enhance immune response against mesothelin-expressing tumor cells (J Thoracic Oncol, Vol 12, Issue 11, S2151). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-64041757 | ADU-214|JNJ-757|Pemlimogene merolisbac | JNJ-64041757 (pemlimogene merolisbac) is a immunotherapy based on live attenuated Listeria monocytogenes, which may enhance immune response against mesothelin-expressing tumor cells (J Thoracic Oncol, Vol 12, Issue 11, S2151). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|